Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKXDOI)

Drug Name
AS602868 Drug Info
Synonyms
Angelicin; ISOPSORALEN; 523-50-2; 2H-Furo[2,3-H]chromen-2-one; Angecin; furo[2,3-h]chromen-2-one; Isopsoralin; Furo(2,3-h)coumarin; Angelecin; Angelicin (coumarin derivative); 2H-Furo[2,3-H]-1-benzopyran-2-one; 2-Oxo-(2H)-furo(2,3-h)-1-benzopyran; UNII-CZZ080D7BD; Angelicin (coumarin deriv); NSC 404563; Furo(5',4':7,8)coumarin; CCRIS 4276; HSDB 3554; 4-Hydroxy-5-benzofuranacrylic acid gamma-lactone; BRN 0153970; CZZ080D7BD; 2H-Furo(2,3-H)-1-benzopyran-2-one; CHEMBL53569; Furo[5',4':7,8]coumarin; Isopsoralen
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Discontinued in Phase 1 [1]
Cross-matching ID
PubChem CID
9820526
CAS Number
CAS 219773-55-4
TTD Drug ID
DMKXDOI

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Monoamine oxidase type B (MAO-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [5]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [6]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [7]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [8]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [9]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [10]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [11]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [12]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [13]
Budipine DMODHQI Migraine 8A80 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Nuclear factor NF-kappa-B (NFKB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [15]
Triptolide DMCMDVR Autoimmune diabetes 5A10 Phase 3 [16]
Laquinimod DM3IWS8 Lupus 4A40 Phase 3 [17]
Edasalonexent DMYVBF6 Duchenne dystrophy 8C70 Phase 3 [18]
MD1003 DMVZ57G Multiple sclerosis 8A40 Phase 3 [18]
Vadimezan DMK7CYX Solid tumour/cancer 2A00-2F9Z Phase 2 [19]
CAT 1004 DMQBP7R Duchenne dystrophy 8C70 Phase 2 [20]
Parthenolide DMCQBFT N. A. N. A. Phase 2 [21]
Recoflavone DMCSR8I Inflammatory bowel disease DD72 Phase 2 [22]
CZEN-002 DMUDMHA Fungal infection 1F29-1F2F Phase 2 [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type A (MAO-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [24]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [25]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [26]
Isocarboxazid DMAF1NB Depression 6A70-6A7Z Approved [27]
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [28]
Psoralen DMIZJ8M N. A. N. A. Phase 3 [2]
CHF-3381 DMQ2O8V Neuropathic pain 8E43.0 Phase 2 [29]
Ladostigil DMJSY3Q Alzheimer disease 8A20 Phase 2 [30]
CX157 DMS2WB5 Mood disorder 6A60-6E23 Phase 2 [31]
PIPERINE DMYEAB1 Vitiligo ED63.0 Phase 1/2 [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Baculoviral IAP repeat-containing protein 5 (BIRC5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [33]
Gefitinib DM15F0X Colon adenocarcinoma Approved [34]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [35]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [36]
Etretinate DM2CZFA Keratosis ED56 Approved [37]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [38]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [39]
Lapatinib DM3BH1Y Breast cancer 2C60-2C65 Approved [40]
Quercetin DM3NC4M Obesity 5B81 Approved [41]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bcl-2-like protein 1 (BCL2L1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [43]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Nitric Oxide DM1RBYG Hypertension BA00-BA04 Approved [36]
Selenium DM25CGV N. A. N. A. Approved [45]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [46]
Methotrexate DM2TEOL Anterior urethra cancer Approved [47]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [48]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [49]
Quercetin DM3NC4M Obesity 5B81 Approved [50]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [51]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [2]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Inhibitor [2]
Nuclear factor NF-kappa-B (NFKB) TTSXVID NFKB1_HUMAN; NFKB2_HUMAN; TF65_HUMAN; RELB_HUMAN; REL_HUMAN Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Gene/Protein Processing [4]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Gene/Protein Processing [4]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009941)
2 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
4 Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer. 2008 Jan 29;98(2):335-44. doi: 10.1038/sj.bjc.6604082. Epub 2008 Jan 8.
5 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
6 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
7 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
9 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
10 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
11 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
12 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
14 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
15 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
16 Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 2001 Nov 29;20(55):8009-18.
17 Reduced astrocytic NF- B activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 2012 Sep;124(3):411-24.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Auckland Cancer Society Research Centre report
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
21 Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med. 2005 Jan 3;201(1):105-15.
22 DA-6034, a derivative of flavonoid, prevents and ameliorates dextran sulfate sodium-induced colitis and inhibits colon carcinogenesis. Exp Biol Med (Maywood). 2008 Feb;233(2):180-91.
23 US patent application no. US20100278784 A1.
24 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
25 Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
26 Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
27 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
28 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
29 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
30 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
31 Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
32 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
33 mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 2008 Oct;99(10):1992-2003. doi: 10.1111/j.1349-7006.2008.00955.x.
34 Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol. 2017 Nov 15;335:16-27. doi: 10.1016/j.taap.2017.09.017. Epub 2017 Sep 21.
35 Assessment of the cytotoxic, genotoxic, and apoptotic potential of flurbiprofen in HeLa and HepG2 cell lines. J Biochem Mol Toxicol. 2021 Jun;35(6):1-11. doi: 10.1002/jbt.22770. Epub 2021 Mar 11.
36 Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
37 Bexarotene activates the p53/p73 pathway in human cutaneous T-cell lymphoma. Br J Dermatol. 2009 Mar;160(3):519-26. doi: 10.1111/j.1365-2133.2008.08931.x. Epub 2008 Nov 25.
38 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
39 Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs. 2011 Oct;29(5):945-52. doi: 10.1007/s10637-010-9450-2. Epub 2010 May 13.
40 Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene. 2005 Sep 15;24(41):6213-21. doi: 10.1038/sj.onc.1208774.
41 Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway. Cancer Invest. 2009 Jul;27(6):604-12. doi: 10.1080/07357900802337191.
42 Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis. 2006 Sep;11(9):1503-12. doi: 10.1007/s10495-006-8896-3.
43 Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
44 Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. Mol Pharmacol. 2005 May;67(5):1808-17. doi: 10.1124/mol.104.005769. Epub 2005 Feb 9.
45 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
46 Role of BAX in the apoptotic response to anticancer agents. Science. 2000 Nov 3;290(5493):989-92. doi: 10.1126/science.290.5493.989.
47 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
48 Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene. 2005 Feb 10;24(7):1231-43. doi: 10.1038/sj.onc.1208290.
49 Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7. doi: 10.1002/ijc.23593.
50 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
51 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.